# RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

> **NCT07366840** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 268 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine
- **DRUG:** Trastuzumab
- **DRUG:** Inetetamab

## Key facts

- **NCT ID:** NCT07366840
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2028-01-16
- **Final completion:** 2029-01-16
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07366840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07366840, "RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07366840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*